Skip to main content

Table 6 Summary of adverse events in the two groups

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Groups Nephrotoxicity (n, %) Hepatotoxicity (n, %) Peripheral neuropathy (n, %) QTc prolongation (n,%) Leukopenia (n, %) hypokalemia (n, %) Ototoxicity (n, %) Others (n, %) p value
Bdq group (n=102) 12 (11.8) 9 (8.8) 3 (3.0) 3(3.0) 2 (2.0) 2 (2.0) 2 (2.0) 4 (3.9) 0.21
Non-Bdq group (n=100) 3 (3.0) 2 (2.0) 1 (1.0) 2(2.0) 2 (2.0) 1 (1.0) 8 (8.0) 7 (7.0)